Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) EBITDA Margin (2020 - 2026)

RxSight filings provide 6 years of EBITDA Margin readings, the most recent being 28.09% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1244.0% to 28.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 29.04%, a 954.0% decrease, with the full-year FY2025 number at 29.04%, down 954.0% from a year prior.
  • EBITDA Margin hit 28.09% in Q4 2025 for RxSight, up from 31.77% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.65% in Q4 2024 to a low of 275.27% in Q2 2021.
  • Median EBITDA Margin over the past 5 years was 61.25% (2023), compared with a mean of 93.95%.
  • The widest YoY moves for EBITDA Margin: up 20481bps in 2021, down -95411bps in 2021.
  • RxSight's EBITDA Margin stood at 186.84% in 2021, then skyrocketed by 48bps to 96.76% in 2022, then skyrocketed by 67bps to 31.92% in 2023, then skyrocketed by 51bps to 15.65% in 2024, then crashed by -80bps to 28.09% in 2025.
  • The last three reported values for EBITDA Margin were 28.09% (Q4 2025), 31.77% (Q3 2025), and 35.43% (Q2 2025) per Business Quant data.